TG Therapeutics, Inc. to Present at Upcoming Investor Conferences
September 21 2017 - 7:30AM
TG Therapeutics, Inc. (NASDAQ:TGTX) today announced its
participation at two upcoming investor conferences. Michael S.
Weiss, the Company’s Executive Chairman and Chief Executive
Officer, is scheduled to present on Monday September 25, 2017 at
1:50pm ET at the Cantor Fitzgerald Global Healthcare Conference,
being held at the InterContinental New York Barclay Hotel in New
York City. Mr. Weiss is also scheduled to present on Tuesday,
September 26, 2017 at 2:30pm ET at the Ladenburg Thalmann 2017
Healthcare Conference, being held at the Sofitel New York Hotel,
also in New York City.
A live webcast of each presentation will be available on the
Events page, located within the Investors & Media section, of
the Company’s website at www.tgtherapeutics.com.
ABOUT TG THERAPEUTICS, INC.
TG Therapeutics is a biopharmaceutical company focused on
the acquisition, development and commercialization of novel
treatments for B-cell malignancies and autoimmune diseases.
Currently, the company is developing two therapies targeting
hematological malignancies and autoimmune diseases. TG-1101
(ublituximab) is a novel, glycoengineered monoclonal antibody that
targets a specific and unique epitope on the CD20 antigen found on
mature B-lymphocytes. TG Therapeutics is also developing
TGR-1202 (umbralisib), an orally available PI3K delta inhibitor.
The delta isoform of PI3K is strongly expressed in cells of
hematopoietic origin and is believed to be important in the
proliferation and survival of B‐lymphocytes. Both TG-1101 and
TGR-1202 are in clinical development for patients with hematologic
malignancies, with TG-1101 also in clinical development for
autoimmune disorders. The Company also has pre-clinical programs to
develop IRAK4 inhibitors, BET inhibitors, and anti-PD-L1
and anti-GITR antibodies. TG Therapeutics is
headquartered in New York City.
TGTX - G
CONTACT:
Jenna BoscoVice President- Investor RelationsTG Therapeutics,
Inc.Telephone: 212.554.4351Email: ir@tgtxinc.com
TG Therapeutics (NASDAQ:TGTX)
Historical Stock Chart
From Aug 2024 to Sep 2024
TG Therapeutics (NASDAQ:TGTX)
Historical Stock Chart
From Sep 2023 to Sep 2024